期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ERCC1和XRCC3基因多态性在接受含铂方案化疗NSCLC中的疗效预测作用 被引量：3

Predictive Role of ERCC1 and XRCC3 Gene Polymorphism on Response of Platinum-based Chemotherapy in Advanced NSCLC
原文传递
导出
摘要 [目的]探讨DNA修复基因ERCC1118和XRCC3241多态性对于接受一线含铂化疗方案的非小细胞肺癌(NSCLC)患者的疗效预测作用。[方法]130例晚期接受含铂化疗的NSCLC患者进入研究,应用Taqman探针结合实时荧光PCR方法分析其外周血基因多态性,分析ERCC1118和XRCC3241多态性与疗效、疾病进展时间和总体生存期之间的关系。[结果]130例患者的总体有效率为20%,中位生存时间为15个月。ERCC1118和XRCC3241多态性与疗效无显著相关性。ERCC1118基因型C/T或T/T患者的生存时间显著延长(P=0.003)。Cox多因素分析显示,ERCC1118基因型C/T或T/T以及化疗有效患者的生存期显著延长。[结论]DNA修复基因ERCC1118基因型C/T或T/T多态性可以延长NSCLC患者铂类治疗后的生存时间。 [Purpose] To investigate the predictive role of ERCC1 118 and XRCC3 241 polymorphism on response in advanced NSCLC patients receiving first-line platinum-based chemotherapy. [ Methods] One hundred and thirty cases with advanced NSCLC treated with platinum-based enrolled in this study, using Taqman probe combined with real time fluorescent PCR detecting gene polymorphism in peripheral blood, analysis of the relationship of ERCC1 118 and XRCC3 241 polymorphism with efficacy, time to progression and overall survival. [Results] The overall response rate was 20%, median survival time was 15 months. There was no significant correlation of ERCC1 118 and XRCC3 241 polymorphism with efficacy. Median survival time in patients with ERCC1 118 genotype C/T or T/T was significant prolonged （P=0.003）.Cox multivariate analysis showed the survival time was significant prolonged in patients with ERCC1 118 genotype C/T or T/T and chemotherapy in effect. [Conclusion] DNA repair gene ERCC1 118 genotype C/T or T/T polymorphism can significantly prolong the overall survival time in patients with NSCLC receiving platinum-based chemotherapy. DNA
作者 任胜祥 周彩存 周崧雯 张玲 苏春霞 张增利 邓沁芳 张颉
机构地区 上海市肺科医院
出处 《肿瘤学杂志》 CAS 2009年第8期706-710,共5页 Journal of Chinese Oncology
基金 上海市科委重大项目基金(06DZ19502)
关键词 DNA修复基因 ERCC1 XRCC3 基因多态性 癌 非小细胞肺 repair gene ERCC1 XRCC3 gene polymorphisms carcinoma, non-small cell lung
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Matullo G,Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32) P-DNA adducts in a sample of healthy subjects [J]. Carcinogenesis, 2001, 22 (9): 1437-1445.
  • 2Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes[J]. Carcinogenesis, 2002, 23(2):295-299.
  • 3Ford BN, Ruttan CC, Kyle VL, et al. Identification of single nucleotide polymorphisms in human DNA repair genes [J]. Carcinogenesis, 2000, 21(11):1977-1981.
  • 4Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer [J]. Ann Oncol, 2004, 15(8):1194-1203.
  • 5Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non- small-cell lung cancer patients treated with cisplatin combination chemotherapy[J].Lung Cancer,2004,44(3):311-316.
  • 6Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92 (3): 205-216.
  • 7Gurubhagavatula S,Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy[J]. J Clin Oncol, 2004, 22(13):2594-2601.
  • 8Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy[J]. Clin Cancer Res, 2004, 10(15):4939-4943.
  • 9Matakidou A, Gaha R, Webb EL, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer[J]. Hum Mol Genet, 2007, 16(19): 2333-2340.
  • 10Rosell-Costa R, Alberola V, Camps C, et al. Clinical outcome of gemcitabine (gem)/cisplatin (cis)-vs docetaxel (doc)/cis-treated stage Ⅳ non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age[J]. J Clin Oncol, 2006, 24(18): 7055.

同被引文献73

  • 1王中华,缪小平,谭文,张湘茹,徐兵河,林东昕.XRCC1单核苷酸多态与晚期非小细胞肺癌对铂类药物化疗敏感性的相关性[J].癌症,2004,23(8):865-868. 被引量：56
  • 2袁芃,缪小平,张雪梅,王中华,谭文,张湘茹,孙燕,徐兵河,林东昕.核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系[J].癌症,2005,24(12):1510-1513. 被引量：46
  • 3项锋钢,柳玉红.VEGF mRNA、KDR mRNA及蛋白在非小细胞肺癌中表达的意义探讨[J].中国现代医学杂志,2007,17(1):63-66. 被引量：4
  • 4Fisher MD, D'Orazio A. Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer, 2000, 2 (1): 21-22.
  • 5Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin and carhoplatin-based doublet chemotherapeutic regimens versus nonplatinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer, 2008, 59(1): 1-11.
  • 6Hildebrandt MA, GuJ, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol, 2009, 5(7): 745-755.
  • 7Nisato RE, Tille JC, Pepper MS. Lymphangiogenesis and tumor metastasis. Tnromb Haemost, 2003, 90(4): 591-597.
  • 8Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer, 2006, 54(3): 267-283.
  • 9Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol, 2007, 22( 13): 2594-2601.
  • 10Luun RM, Langlois RG, Hsieh LL, et al. XRCC1 polymorphisms effects on aflatoxin B 1-DNA adducts and glycophorin a variant frequency. Cancer Res, 1999, 59(11): 2557-2561.

引证文献3

二级引证文献21

肿瘤学杂志
2009年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部